Zevra Denmark A/S: Financial statements 2023
CVR: 43259326
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
Zevra Denmark A/S (CVR 43259326) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -12,548,000 and a net result of DKK -20,506,000. Equity in the 2023 report amounted to DKK -27,513,000. The company had 6 employees in the financial year.
- Gross Profit
- DKK -12,548,000
- Profit/Loss
- DKK -20,506,000
- Equity
- DKK -27,513,000
- Total Assets
- DKK 189,146,000
- Employees
- 6
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
Zevra Denmark A/S has published its interim report for the period May 13, 2022 to December 31, 2022.
As of May 23, 2023, EY Godkendt Revisionspartnerselskab has been appointed auditor of Zevra Denmark A/S.
As of May 23, 2023, RSM DANMARK STATSAUTORISERET REVISIONSPARTNERSELSKAB has stepped down as auditor of Zevra Denmark A/S.
On February 22, 2023, the company changed its name from KemPharm Denmark A/S to Zevra Denmark A/S.
About Zevra Denmark A/S
Zevra Denmark A/S is a Danish company of the type Aktieselskab based in Frederiksberg, founded in 2022. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named KemPharm Denmark A/S. The management consists of Timothy Sangiovanni. The board consists of Rahsaan Waleed Thompson (chair), Justin Andrew Renz, Thomas Weitemeyer and Timothy Sangiovanni. The company is owned by Zevra Therapeutics, Inc.. The company has 4 employees (2026). In 2025, the company reported revenue of DKK 123,335,000 and a net result of DKK 334,468,000 compared with DKK -132,114,000 the year before. Equity in the 2025 report amounted to DKK 174,841,000.